CONFERENCE AGENDA -- WEDNESDAY, MAY 10


WEDNESDAY MAY 10          THURSDAY MAY 11

TIME PROGRAM LOCATION
7:00AM-5:00PM CHECK-IN AND REGISTRATION REGISTRATION DESK
8:30AM-10:30AM

OPENING KEYNOTE & PANEL
Malcolm Gladwell

Panel discussion

Sponsored by

COLUMBUS ROOM
10:30AM-5:00PM 1x1 PARTNERING PARTNERING ZONE
10:30AM-11:00AM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY
AN INTRODUCTION TO NEW YORK'S LIFE SCIENCE INITIATIVES

TOWER EAST

PITCHFEST, SESSION 1

Efferent Labs was founded in 2011 to delivery better, more informed healthcare to those in need through real-time monitoring of personal well-being. The core technology was invented by Dr. Spencer Rosero at the University of Rochester. Today, Efferent continues to make advancements with research teams at the University of Rochester as well as the University at Buffalo. Efferent has 4 issued patents with other patents pending and in the pipeline. Most recently, Efferent announced a development and commercialization agreement with Evotec AG.
Yiviva was founded in October 2015 by Yale University and Yung-Chi Cheng (PhD), Peikwen Cheng (MBA), Shwu-Huey Liu (PhD). Dr Cheng has discovered four approved drugs including the first drug for Hepatitis B (HBV) and Cytomegalovirus (CMV). Yiviva has licensed Yale and Dr Cheng's portfolio of breakthrough discoveries and technologies in botanical medicine to develop poly-target medicines to address complex diseases, including cancer and chronic diseases.

 

TOWER WEST

HUDSON ROOM

REVERSE PITCH:
WORKING WITH PFIZER: EARLY R&D INTERACTIONS BETWEEN ACADEMIA AND INDUSTRY
CITY ROOM
11:00AM-11:30AM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY:

TOWER EAST

PITCHFEST, SESSION 2

Motion Intelligence Inc. was founded by Richard Uhlig in 2012. The company currently has 17 employees and is located in the Institute for Human Performance on the SUNY Upstate Medical University campus. The company has developed a clinical assessment system for concussion injuries (pending FDA clearance) and is developing epigenetic biomarkers for a variety of neurological disorders and injuries, including Autism Spectrum Disorder, Parkinson's Disease and Concussions. The company?s technology is developed in-house and through sponsored research agreements with several academic research institutions.
A NYC based company developing a new class of therapeutics derived from GRAS compounds. Innovene is now poised to introduce TriCurin - an anti-viral therapeutic against HPV and HPV originated cancers - into the cancer prevention & treatment marketplace. Founded in 2016, Patent owner: Research Foundation of the City University of New York and the Feinstein Institute for Medical Research. Innovene will have the exclusive license rights.

 

TOWER WEST

HUDSON ROOM

REVERSE PITCH:
WORKING WITH JOHNSON & JOHNSON
CITY ROOM
11:30AM-12:00PM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY
NEW YORK CITY

  • Carlo Yuvienco, New York City Economic Development Corp.
TOWER EAST

PITCHFEST, SESSION 3

Bioharmony Therapeutics, incorporated in 2016, is an early stage biotech startup focused on the development of novel antimicrobials, called lysins which are enzymes isolated from bacteriophages. Antibiotic resistance is a global public health problem leading to 700,000 deaths per year from infections that can no longer be treated with available antibiotics. Lysins, are the solution to this problem. Our first product is a topical lysin against MDR Acinetobacter baumannii infections in burn patients. Our pipeline includes lysins against pneumonia and UTI. Our technology is licensed from Rockefeller University. Our team has decades worth of experience in drug discovery and development.
DelNova, founded in 2016, is focused on applying drug delivery expertise for superior therapeutic benefit and a more competitive drug product profile. The first product under development is a repurposed drug, to be used for the reversal of undesirable side effects resulting from neurotoxin injections [ie. Botulinum type A toxin (BTX), e.g. Botox]. These undesirable side effects are evident in both cosmetic and medical applications. A rescue product has the potential to grow the $4 billion neurotoxin market. DelNova is seeking seed stage financing to progress preclinical studies to a human pilot study.

 

TOWER WEST

HUDSON ROOM

REVERSE PITCH:
WORKING WITH SANOFI
CITY ROOM
12:00PM-1:30PM
LUNCHEON PROGRAM:

TIPPING PERCEPTIONS: HOW CAN NEW YORK STATE BECOME THE IDEAL LIFE SCIENCE HUB OF THE US

COLUMBUS ROOM
1:30PM-2:00PM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY:
BUFFALO AND WESTERN NY

  • Kim Grant, University of Buffalo
TOWER EAST

PITCHFEST, SESSION 4

Lewis H. Bender founded the company in 2012 based on his idea for a new way of treating cancer. The founder put his own money into the company to conduct the first experiments using contracted laboratories. After the first data set, friends, neighbors and family began to invest. The National Cancer Institute awarded the small company a CRADA in 2014 to help investigate the novel drug therapy. In less than 5 years since its founding, the company raised over $13.3 million, had two US patents granted, identified a lead drug from its novel platform, completed nonclinical studies, scaled GMP manufacturing, filed an accepted IND with FDA & a CTA with HC and began trials in 2017. The first human clinical study (US and Canada) is fully funded.
CytoDel's technology platform was developed by its NYU founders in response to a Tier 1 biodefense threat: weaponized botulinum neurotoxin (BoNT, aka Botox). Founded in 2012, CytoDel holds exclusive license to 5 issued US patents, issued foreign patents, and applications still under prosecution. The technology and manufacturing infrastructure is broadly applicable to large pharmaceutical markets. CytoDel's lead biodefense product, Cyto-111, is the first therapeutic ever shown to revere respiratory symptoms of botulism. It is being co-developed under a CRADA with DoD. An Animal Rule IND is planned by 2019, with revenue generation expected to commence by 2020.

 

TOWER WEST

CIRCLE ROOM

REVERSE PITCH:
WORKING WITH MERCK
CITY ROOM
2:00PM-2:30PM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY:
CAPITAL REGION AND HUDSON VALLEY

  • Andrew Kennedy, BioConnex / CEG
TOWER EAST

PITCHFEST, SESSION 5

The company has developed proprietary point of care devices and compositions for detection and mitigation of unwanted antibody (Ab) responses against therapeutic proteins. Those Ab responses can negatively impact drug efficacy and/or safety. ConquerAb's technology can be used to compare drugs marketed for the same application. An alpha prototype is available, which allows detection of anti-drug antibodies in one drop of blood.
Parkside designs and optimizes small molecule drug cures for deadly cancers (Triple-Negative Breast (TNBC) & Prostate) and other diseases (Inflammatory Bowel Disease (IBD), Diabetes, Obesity) by novel epigenetic approach of turning genes "on/off" through modulating protein signaling. Core competence is designing novel IP protected drugs, taking them to IND/Phase 1 Human Clinical Trials, and handing them off to larger pharma. Our most advanced program is for TNBC, which has no drug cure; existing Standard of Care is chemo/surgery. Annual Market for TNBC Drug >$5Bil (est.) Working towards IND filing/ commencement Phase 1 Trials around end of 2018. Annual Market for IBD drugs >$9.7Bil (est.)

 

TOWER WEST

CIRCLE ROOM

REVERSE PITCH:
ROCHE : INNOVATIVE PARTNERING MODEL
CITY ROOM
STUDENT & POST DOC CAREER SYMPOSIUM HUDSON ROOM
2:30PM-3:00PM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY:
SUNY DOWNSTATE INCUBATOR AND BIOBAT

  • Baptiste Aussedat, PhD, CEO and Co-Founder,  Chemitope  Glycopeptide, LLC 

  • Stacy Blain, CSO and Co-Founder,  Concarlo Holdings, LLC

  • Jeffrey Gardner, CEO and Co-Founder,  Adjuvance Technologies, Inc.

  • Christopher Marshall, PhD, CEO and Founder, Avatar Biotechnologies

  • Christopher Parks, PhD, Executive Director, The International AIDS Vaccine Initiative

  • Nina Tandon,  PhD, CEO and Co-Founder, EpiBone, Inc.

  • Kevin Tyan, PhD, CTO and Co-Founder,  Kinnos, Inc.

  • Moderator: Eva Cramer, PhD, President of Downstate Biotechnology Incubator and BioBAT

  • Kathleen Otto, Executive Director of BioBAT

TOWER EAST

PITCHFEST, SESSION 6

We are targeting the >$2BN cell line development market space, in particular manufacturing of biopharmaceuticals, with a cell line selection protocol that should speed up and lower the costs and efforts involved in creating a stable cell line. Our product, PTSelect, essentially replaces antibiotic resistance to perform selection with an siRNA. Selection is subsequently performed using transfected mRNA and magnetic isolation, depletion, FACS, or cell death. The techniques can also be used for cell separation of stem cells and other cell types for therapeutic purposes.
Founded in 2014, PathoVax LLC is developing breakthrough vaccines against infectious diseases and cancers utilizing a Human Papillomavirus Virus-Like Particle (HPV VLP) platform that has been exclusively licensed from the Johns Hopkins University. This technology is generated by the same investigators responsible for existing HPV vaccines, and can be used to present other antigens to induce robust humoral or cellular immune responses against multiple infectious agents and tumors. Our lead candidate (RGVax) is a patented, universal HPV vaccine that targets all clinically-relevant HPVs while sidestepping uptake challenges to more than double a global market with over $2B in annual revenues.

 

TOWER WEST

CIRCLE ROOM

REVERSE PITCH:
WORKING WITH ELI LILLY
CITY ROOM
STUDENT & POST DOC CAREER SYMPOSIUM HUDSON ROOM
3:00PM-3:15PM NETWORKING BREAK
3:15PM-3:45PM CONCURRENT SESSIONS
BUILDING BIOTECH IN NEW YORK:

INNOVATION FROM SCIENCE AND BUSINESS TO BUSINESS

  • Michelle van de Walle, Cornell Center for Materials Research
  • Susi Varvayanis, Cornell University
  • Michael Riedlinger, Rochester Bio Venture Center, & High Tech Rochester (HTR) Technology Commericlaization
  • Alice Li, Cornell Center for Technology Licensing
  • Stephane Corgie, Zymtronix
TOWER EAST

PITCHFEST, SESSION 7

ViRAZE (UPenn PCI, 2015) discovers and develops first-in-class small molecules to treat virus-induced dermatology diseases. Our technology platform is based on inhibiting the DNA replication of viruses, with a legacy program for smallpox, which is funded by a $2 million NIH grant. Our lead commercial pre-clinical program is for the first approved drug to treat the painful and contagious skin disease Molluscum contagiosum, and is funded by a $3 million NIH grant. Current MC treatment relies on off-label drugs, and painful cauterization. Estimated US sales for the product are $400 million.
The company has discovered and invented a scaffold technology that uses microspheres embedded in a collagen hydrogel to create and maximize the number of differential density interfaces within the scaffold. It is these differential density interfaces that drive the cell invasion into the scaffold.

 

TOWER WEST

CIRCLE ROOM

REVERSE PITCH:
WORKING WITH NOVO NORDISK
CITY ROOM
STUDENT & POST DOC CAREER SYMPOSIUM HUDSON ROOM
3:45PM-4:35PM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY:
NEW MODELS FOR NY LIFE SCIENCE COMMERCIALIZATION

  • Mary Howard, eLab NYC
  • Kathleen Dennis, Rockefeller University
  • Robert Schneider, NYU School of Medicine
  • Peter Donnelly, Stony Brook University
  • Kim Grant, University of Buffalo
  • Marc Alessi, Business Incubator Association New York State
TOWER EAST

PITCHFEST, SESSION 8

Our lead compound is an accelerated, short-development track, anti-cancer agent (nano-fenretinide) delivered in a novel, intravenous system initially for the management of an orphan lymphoma (cutaneous T-Cell) and then for a cadre of other tumor-types of unmet need. Originally associated with the Karmanos Cancer Institute (KCI) and Wayne State University (WSU), SciTech was tasked with addressing the therapeutic performance limitations of fenretinide namely, the inability to deliver effective doses safely.

 

TOWER WEST

CIRCLE ROOM

REVERSE PITCH:
WORKING WITH CHARLES RIVER: EVERY STEP OF THE WAY
CITY ROOM
STUDENT & POST DOC CAREER SYMPOSIUM HUDSON ROOM
4:40PM-5:30PM CONCURRENT SESSIONS

BUILDING BIOTECH IN NY:
RESEARCH FOUNDATIONS WITH INNOVATIVE BUSINESS MODELS IN NEW YORK

Medical foundations have raised and distributed billions of dollars of research funding. Historically the funding was mainly directed to grants to fund research at the academic centers. Over the past few years, disease based foundations have become increasingly more influential and some of them currently play an instrumental role in the research and development process of their disease area of interest. Moreover, the most innovative foundations are no longer grant distributors but run as non- profit enterprises with very creative business models.  

Today, New York is uniquely positioned to be highly successful in the R&D process because New York hosts a plethora of creative foundations, an increasing number of highly successful biotechnology companies, an increasing presence of large pharma and a wealth of top academic institutions. 

Together with the fact that New Yorkers are highly philanthropic, there is a unique opportunity to create a premier landscape to strategically involve all the key stakeholders in accelerating the path from basic discovery to effective treatments. The current panel will highlight some of the creative public private partnerships that have become a reality in NYC.

  • Annette Bakker, CEO, Children's Tumor Foundation
  • Michael Batten, Director, T1D Fund, JDRF
  • Susan Solomon, Co-Founder and CEO, The New York Stem Cell Foundation 
  • Sohini Chowdhury, Deputy CEO, The Michael J. Fox Foundation for Parkinson’s Research
  • Lara Sullivan, Vice President, Pfizer
TOWER EAST

PITCHFEST, SESSION 9

Founded in 2015, PainQx has developed an accurate, objective and reproducible method to measure pain in humans. PQx's patented technology delivers a real-time pain score to clinical users via cloud-based software on a pay-per-use or subscription basis. The output is directly correlated to a patient?s pain state. The system is currently being used by researchers to assess pain as a primary or secondary clinical end point to measure therapeutic efficacy. Upon FDA clearance, PainQx will work with hospitals, physicians and pain centers who serve chronic pain patients. There are over 116 million chronic pain patients in the US alone.
Mousensor, LLC is an early-stage biotech company that engineers super sniffer mice to build a human-nose-on-a-chip based on proprietary technology developed at the Feinstein lab for Neurogenetics at Hunter College, CUNY. The company’s goal is to digitize the human sense of smell, much like the CMYK color code for vision, and to identify the unique odor codes for each individual odor mixture that exists on this planet; ranging from the fragrances in a perfumer’s palette to the Chardonnay in your wine cellar. The company currently focuses on 3 areas: 1. Flavor & Fragrance Industry: an olfactory code to predict the “smell” of certain odor mixtures and to re-engineer new compounds in a rational and more streamlined manner (recommended for SBIR Phase I NSF funding). 2. Military & Defense: super sniffers to detect explosives (funded through DARPA) 3. Pharma: a bioassay to detect disease-specific odors (funded through the Michael J Fox Foundation for Parkinson’s Research)

 

TOWER WEST

CIRCLE ROOM

5:30PM-7:30PM OPENING RECEPTION
Sponsored by
                 
COLUMBUS ROOM

WEDNESDAY MAY 10          THURSDAY MAY 11

Schedule and agenda are subject to change